Antibodies directed against actress and actress
CL202600889A1Pending Publication Date: 2026-08-07SIXPEAKS BIO AG
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- CL202600889
- Authority / Receiving Office
- CL · CL
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-09-27
- Filing Date
- 2026-03-25
- Publication Date
- 2026-08-07
Abstract
This description relates to antibodies and antibody fragments specific for ActRIIA and ActRIIB. The antibodies are enhanced versions of bimagrumab. The antibodies of the present invention have improved affinity for ActRIIA, resulting in enhanced in vitro potency and efficacy, an improved PK and PD profile, and greater stability, making the antibodies suitable for subcutaneous administration. Optionally, they carry Fc modifications that make the antibodies safe for treatment.
Need to check novelty before this filing date? Find Prior Art